Survival benefit of thoracic radiotherapy plus EGFR-TKIs in patients with non-oligometastatic advanced non-small-cell lung cancer: a single-center retrospective study

医学 放射治疗 内科学 肺癌 肺炎 肿瘤科 回顾性队列研究 表皮生长因子受体 队列 单中心 癌症 肺
作者
Fangyuan Zhou,You Qin,Xixi Liu,Jing Huang,Bian Wu,Zhanjie Zhang,Zhongyuan Yin,Jinsong Yang,Sheng Zhang,Ke Jiang,Kunyu Yang
出处
期刊:Therapeutic Advances in Medical Oncology [SAGE Publishing]
卷期号:15: 17588359231161411-17588359231161411 被引量:10
标识
DOI:10.1177/17588359231161411
摘要

Objectives: The study aims to evaluate the efficacy and safety of thoracic radiotherapy in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-treated patients with stage IV non-small-cell lung cancer (NSCLC). Methods: Patients with non-oligometastatic NSCLC harboring EGFR mutations were recruited. All patients received the first-generation TKI treatment with or without radiotherapy. The irradiated sites included primary and/or metastatic lesions. Of all the patients who underwent thoracic radiotherapy, some received radiotherapy before EGFR-TKI resistance, others received radiotherapy after progressive disease. Results: No statistically significant difference was observed in progression-free survival (PFS) (median 14.7 versus 11.2 months, p = 0.075) or overall survival (OS) (median 29.6 versus 40.6 months, p = 0.116) between patients treated with EGFR-TKIs alone and those with additional radiotherapy to any sites. However, EGFR inhibitors with thoracic radiation significantly improved OS (median 47.0 versus 31.0 months, p < 0.001) but not PFS (median 13.9 versus 11.9 months, p = 0.124). Moreover, longer PFS (median 18.3 versus 8.5 months, p < 0.001) was achieved in the preemptive thoracic radiation cohort than in the delayed thoracic radiation cohort. However, OS was similar between the two cohorts (median 40.6 versus 52.6 months, p = 0.124). The lower incidence rate of grade 1–2 pneumonitis occurred in preemptive radiation cohort (29.8% versus 75.8%, p < 0.001). Conclusion: Non-oligometastatic NSCLC patients with EGFR mutations benefited from thoracic radiotherapy while using EGFR inhibitors. Preemptive thoracic radiotherapy could be a competitive first-line therapeutic option due to superior PFS and favorable safety.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
星辰大海的应助被科研通管家采纳,获得10
刚刚
充电宝的应助被愉快数据线采纳,获得10
刚刚
研友_VZG7GZ的应助被科研通管家采纳,获得10
1秒前
白糖发布了新的文献求助10
1秒前
脑洞疼的应助被科研通管家采纳,获得10
1秒前
lizzie发布了新的文献求助10
1秒前
皮卡丘发布了新的文献求助30
1秒前
作业本的应助被科研通管家采纳,获得10
1秒前
爆米花的应助被科研通管家采纳,获得10
1秒前
星辰大海的应助被科研通管家采纳,获得10
1秒前
1秒前
田様的应助被科研通管家采纳,获得10
1秒前
Lucas的应助被科研通管家采纳,获得10
2秒前
思源的应助被科研通管家采纳,获得10
2秒前
烂漫的从彤完成签到,获得积分10
2秒前
所所的应助被科研通管家采纳,获得10
2秒前
李远锐完成签到 ,获得积分10
2秒前
CipherSage的应助被科研通管家采纳,获得10
2秒前
小蘑菇的应助被科研通管家采纳,获得10
2秒前
2秒前
3秒前
糜厉完成签到,获得积分10
3秒前
蔡莹发布了新的文献求助10
3秒前
北海完成签到,获得积分10
4秒前
wanci的应助被下午茶采纳,获得30
4秒前
LZU_Dai完成签到,获得积分10
5秒前
科研通AI65的应助被obito采纳,获得10
5秒前
5秒前
zzx123完成签到,获得积分20
5秒前
ubless607给南楼小阁主的求助进行了留言
6秒前
6秒前
Akim的应助被光电效应采纳,获得10
6秒前
Angleli完成签到,获得积分10
7秒前
dyy123发布了新的文献求助10
7秒前
一一完成签到,获得积分20
7秒前
7秒前
科研通AI6.3的应助被keyanbutong采纳,获得10
7秒前
boom完成签到,获得积分10
8秒前
zhouhuan完成签到 ,获得积分10
8秒前
健壮的大有完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182102
求助须知:如何正确求助?哪些是违规求助? 9571775
关于积分的说明 21819723
捐赠科研通 7778500
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479651